You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLatanoprost
Accession NumberDB00654  (APRD01065)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLatanoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It is also known by the brand name of Xalatan manufactured by Pfizer.
Structure
Thumb
Synonyms
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Latanoprost
Latanoprostum
PhXA 41
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Xalatan
External Identifiers
  • PHXA 41
  • XA 41
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Latanoprostsolution0.05 mgophthalmicActavis Pharma Company2011-10-13Not applicableCanada
Bl Latanoprostsolution50 mcgophthalmicBausch & Lomb IncNot applicableNot applicableCanada
Gd-latanoprostsolution50 mcgophthalmicGenmed A Division Of Pfizer Canada Inc2011-10-03Not applicableCanada
Jamp-latanoprostsolution50 mcgophthalmicJamp Pharma CorporationNot applicableNot applicableCanada
Latanoprostsolution50 ug/mLophthalmicGreenstone LLC1995-03-20Not applicableUs
Latanoprostsolution50 mcgophthalmicLaboratoire Riva IncNot applicableNot applicableCanada
Latanoprost Ophthalmic Solutionsolution50 mcgophthalmicAlcon Canada IncNot applicableNot applicableCanada
Med-latanoprostsolution50 mcgophthalmicGeneric Medical Partners Inc2015-01-09Not applicableCanada
Mint-latanoprostsolution50 mcgophthalmicMint Pharmaceuticals IncNot applicableNot applicableCanada
Monoprostsolution50 mcgophthalmicLaboratoires TheaNot applicableNot applicableCanada
PMS-latanoprostsolution50 mcgophthalmicPharmascience Inc2014-10-23Not applicableCanada
Riva-latanoprostsolution50 mcgophthalmicLaboratoire Riva Inc2015-05-11Not applicableCanada
Sandoz Latanoprostsolution50 mcgophthalmicSandoz Canada Incorporated2011-12-06Not applicableCanada
Taro-latanoprostsolution50 mcgophthalmicTaro Pharmaceuticals IncNot applicableNot applicableCanada
Teva-latanoprostsolution50 mcgophthalmicTeva Canada LimitedNot applicableNot applicableCanada
Xalatansolution50 ug/mLophthalmicPharmacia And Upjohn Company Llc1995-03-20Not applicableUs
Xalatansolution50 ug/mLophthalmicDispensing Solutions, Inc.1995-03-20Not applicableUs
Xalatansolution50 mcgophthalmicPfizer Canada Inc1997-07-28Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-latanoprostsolution50 mcgophthalmicApotex Inc2011-10-03Not applicableCanada
Latanoprostsolution/ drops50 ug/mLophthalmicPhysicians Total Care, Inc.2011-06-21Not applicableUs
Latanoprostsolution50 ug/mLophthalmicMylan Pharmaceuticals Inc.2011-03-22Not applicableUs
Latanoprostsolution/ drops50 ug/mLophthalmicRebel Distributors Corp2011-03-22Not applicableUs
Latanoprostsolution50 ug/mLophthalmicSandoz Inc2011-01-07Not applicableUs
Latanoprostsolution50 ug/mLophthalmicAmerican Regent, Inc.2011-08-02Not applicableUs
Latanoprostsolution/ drops50 ug/mLophthalmicBausch & Lomb Incorporated2011-03-22Not applicableUs
Latanoprostsolution/ drops50 ug/mLophthalmicMwi2015-04-08Not applicableUs
Latanoprostsolution/ drops50 ug/mLophthalmicREMEDYREPACK INC.2013-06-12Not applicableUs
Latanoprostsolution/ drops50 ug/mLophthalmicAkorn, Inc.2012-07-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArulatanDr. Gerhard Mann
GaapSophia
Gaap OftenoSophia
GaaxChile
GlaucogesicAtlas
GlaumaxKevelt
GlauprostArrow
HysitePfizer
IopizeSIFI
IoprostFDC
IoptameCadila
KlonaprostKlonal
LanoprostSynpac-Kingdom
LanotanKuk Je
LaprostOftalmi
LatacrisSun-Farm
LataluxJelfa
Latan-OphtalWinzer
LataneauAlapis Pharma
Brand mixtures
NameLabellerIngredients
Act Latanoprost/timololActavis Pharma Company
Apo-latanoprost-timopApotex Inc
Gd-latanoprost/timololGenmed A Division Of Pfizer Canada Inc
Jamp-latanoprost/timololJamp Pharma Corporation
Med-latanoprost-timololGeneric Medical Partners Inc
Mint-latanoprost/timololMint Pharmaceuticals Inc
Mylan-latanoprost/timololMylan Pharmaceuticals Ulc
PMS-latanoprost-timololPharmascience Inc
Sandoz Latanoprost/timololSandoz Canada Incorporated
Teva-latanoprost/timololTeva Canada Limited
XalacomPfizer Canada Inc
SaltsNot Available
Categories
UNII6Z5B6HVF6O
CAS number130209-82-4
WeightAverage: 432.5928
Monoisotopic: 432.28757439
Chemical FormulaC26H40O5
InChI KeyInChIKey=GGXICVAJURFBLW-CEYXHVGTSA-N
InChI
InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
IUPAC Name
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
SMILES
CC(C)OC(=O)CCC\C=C/C[[email protected]]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Fatty acid ester
  • Benzenoid
  • Cyclopentanol
  • Monocyclic benzene moiety
  • Cyclic alcohol
  • Secondary alcohol
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
PharmacodynamicsLatanoprost is an isopropyl ester prodrug which is inactive but which becomes active after hydrolysis to the acid from. Latanoprost opthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.
Mechanism of actionLatanoprost is a prostaglandin F2a analogue. Specifically, Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Related Articles
AbsorptionLatanoprost is well absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form. Peak concentration is reached 2 hrs after topical administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1,2-dinor and 1,2,3,4-tetranor metabolites by fatty acid beta-oxidation.

Route of eliminationNot Available
Half life17 minutes
Clearance
  • 7 mL/min/kg
ToxicitySymptoms of overdose include bloodshot eyes and eye irritation.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9474
Blood Brain Barrier+0.6512
Caco-2 permeable+0.5337
P-glycoprotein substrateSubstrate0.5728
P-glycoprotein inhibitor INon-inhibitor0.8684
P-glycoprotein inhibitor IINon-inhibitor0.7124
Renal organic cation transporterNon-inhibitor0.8805
CYP450 2C9 substrateNon-substrate0.7819
CYP450 2D6 substrateNon-substrate0.8835
CYP450 3A4 substrateSubstrate0.5947
CYP450 1A2 substrateNon-inhibitor0.8845
CYP450 2C9 inhibitorNon-inhibitor0.7724
CYP450 2D6 inhibitorNon-inhibitor0.8985
CYP450 2C19 inhibitorNon-inhibitor0.7236
CYP450 3A4 inhibitorNon-inhibitor0.7393
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7405
Ames testNon AMES toxic0.8324
CarcinogenicityNon-carcinogens0.9379
BiodegradationNot ready biodegradable0.6353
Rat acute toxicity4.3748 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9071
hERG inhibition (predictor II)Non-inhibitor0.8763
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Solutionophthalmic0.05 mg
Solutionophthalmic50 ug/mL
Solution/ dropsophthalmic50 ug/mL
Solutionophthalmic
Solutionophthalmic50 mcg
Prices
Unit descriptionCostUnit
Xalatan 0.005% Solution 2.5ml Bottle93.59USD bottle
Xalatan 0.005% eye drops45.06USD ml
Xalatan 0.005 % Solution12.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1339132 No1997-07-292014-07-29Canada
US5296504 No1994-03-222011-03-22Us
US6429226 No1992-09-062009-09-06Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
water solubility8 mg/mLNot Available
logP4.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0129 mg/mLALOGPS
logP4.16ALOGPS
logP3.98ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)14.47ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.99 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity124.34 m3·mol-1ChemAxon
Polarizability50.71 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Arie Gutman, “Process for the preparation of latanoprost.” U.S. Patent US20030149294, issued August 07, 2003.

US20030149294
General References
  1. Hara T: [Increased iris pigmentation after use of latanoprost in Japanese brown eyes]. Nippon Ganka Gakkai Zasshi. 2001 May;105(5):314-21. [PubMed:11406947 ]
External Links
ATC CodesS01EE01
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (502 KB)
MSDSDownload (21.1 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Latanoprost.
AcebutololLatanoprost may increase the hypotensive activities of Acebutolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Latanoprost.
AliskirenLatanoprost may increase the hypotensive activities of Aliskiren.
AlprenololLatanoprost may increase the hypotensive activities of Alprenolol.
AmbrisentanLatanoprost may increase the hypotensive activities of Ambrisentan.
AmifostineLatanoprost may increase the hypotensive activities of Amifostine.
AmlodipineAmlodipine may increase the hypotensive activities of Latanoprost.
AtenololAtenolol may increase the hypotensive activities of Latanoprost.
BenazeprilBenazepril may increase the hypotensive activities of Latanoprost.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Latanoprost.
BenmoxinBenmoxin may increase the hypotensive activities of Latanoprost.
BepridilLatanoprost may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Latanoprost.
BethanidineBethanidine may increase the hypotensive activities of Latanoprost.
BimatoprostLatanoprost may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Latanoprost.
BosentanBosentan may increase the hypotensive activities of Latanoprost.
BretyliumLatanoprost may increase the hypotensive activities of Bretylium.
BrimonidineLatanoprost may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Latanoprost.
BupranololLatanoprost may increase the hypotensive activities of Bupranolol.
CandesartanLatanoprost may increase the hypotensive activities of Candesartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Latanoprost.
CaptoprilLatanoprost may increase the hypotensive activities of Captopril.
CaroxazoneCaroxazone may increase the hypotensive activities of Latanoprost.
CarteololCarteolol may increase the hypotensive activities of Latanoprost.
CarvedilolLatanoprost may increase the hypotensive activities of Carvedilol.
CeliprololLatanoprost may increase the hypotensive activities of Celiprolol.
ChlorothiazideLatanoprost may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Latanoprost.
CilazaprilLatanoprost may increase the hypotensive activities of Cilazapril.
ClonidineClonidine may increase the hypotensive activities of Latanoprost.
CryptenamineLatanoprost may increase the hypotensive activities of Cryptenamine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Latanoprost.
DebrisoquinLatanoprost may increase the hypotensive activities of Debrisoquin.
DeserpidineLatanoprost may increase the hypotensive activities of Deserpidine.
DiazoxideDiazoxide may increase the hypotensive activities of Latanoprost.
DiltiazemDiltiazem may increase the hypotensive activities of Latanoprost.
DorzolamideLatanoprost may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Latanoprost.
EfonidipineLatanoprost may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Latanoprost.
EnalaprilatLatanoprost may increase the hypotensive activities of Enalaprilat.
EpoprostenolLatanoprost may increase the hypotensive activities of Epoprostenol.
EprosartanLatanoprost may increase the hypotensive activities of Eprosartan.
FelodipineLatanoprost may increase the hypotensive activities of Felodipine.
FenoldopamLatanoprost may increase the hypotensive activities of Fenoldopam.
FosinoprilFosinopril may increase the hypotensive activities of Latanoprost.
FurazolidoneFurazolidone may increase the hypotensive activities of Latanoprost.
GuanabenzGuanabenz may increase the hypotensive activities of Latanoprost.
GuanadrelGuanadrel may increase the hypotensive activities of Latanoprost.
GuanethidineLatanoprost may increase the hypotensive activities of Guanethidine.
GuanfacineLatanoprost may increase the hypotensive activities of Guanfacine.
HexamethoniumLatanoprost may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Latanoprost.
HydralazineLatanoprost may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideLatanoprost may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideLatanoprost may increase the hypotensive activities of Hydroflumethiazide.
IloprostIloprost may increase the hypotensive activities of Latanoprost.
IndapamideLatanoprost may increase the hypotensive activities of Indapamide.
IndenololLatanoprost may increase the hypotensive activities of Indenolol.
IndoraminLatanoprost may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Latanoprost.
IproniazidIproniazid may increase the hypotensive activities of Latanoprost.
IrbesartanLatanoprost may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Latanoprost.
IsradipineIsradipine may increase the hypotensive activities of Latanoprost.
LabetalolLabetalol may increase the hypotensive activities of Latanoprost.
LacidipineLatanoprost may increase the hypotensive activities of Lacidipine.
LercanidipineLercanidipine may increase the hypotensive activities of Latanoprost.
LisinoprilLatanoprost may increase the hypotensive activities of Lisinopril.
LofexidineLatanoprost may increase the hypotensive activities of Lofexidine.
LosartanLatanoprost may increase the hypotensive activities of Losartan.
MacitentanLatanoprost may increase the hypotensive activities of Macitentan.
ManidipineLatanoprost may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Latanoprost.
MecamylamineLatanoprost may increase the hypotensive activities of Mecamylamine.
MethyldopaLatanoprost may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Latanoprost.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Latanoprost.
MetipranololLatanoprost may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Latanoprost.
MetoprololMetoprolol may increase the hypotensive activities of Latanoprost.
MibefradilLatanoprost may increase the hypotensive activities of Mibefradil.
MinaprineMinaprine may increase the hypotensive activities of Latanoprost.
MinoxidilMinoxidil may increase the hypotensive activities of Latanoprost.
MoclobemideMoclobemide may increase the hypotensive activities of Latanoprost.
MoexiprilLatanoprost may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Latanoprost.
MoxonidineLatanoprost may increase the hypotensive activities of Moxonidine.
NadololLatanoprost may increase the hypotensive activities of Nadolol.
NebivololLatanoprost may increase the hypotensive activities of Nebivolol.
NialamideNialamide may increase the hypotensive activities of Latanoprost.
NicardipineNicardipine may increase the hypotensive activities of Latanoprost.
NicorandilLatanoprost may increase the hypotensive activities of Nicorandil.
NiguldipineLatanoprost may increase the hypotensive activities of Niguldipine.
NilvadipineLatanoprost may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Latanoprost.
NisoldipineNisoldipine may increase the hypotensive activities of Latanoprost.
NitrendipineLatanoprost may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Latanoprost.
ObinutuzumabLatanoprost may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Latanoprost.
OlmesartanOlmesartan may increase the hypotensive activities of Latanoprost.
OmapatrilatLatanoprost may increase the hypotensive activities of Omapatrilat.
OxprenololLatanoprost may increase the hypotensive activities of Oxprenolol.
PargylineLatanoprost may increase the hypotensive activities of Pargyline.
PenbutololLatanoprost may increase the hypotensive activities of Penbutolol.
PentoliniumLatanoprost may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Latanoprost.
PerindoprilLatanoprost may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Latanoprost.
PheniprazinePheniprazine may increase the hypotensive activities of Latanoprost.
PhenoxybenzamineLatanoprost may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Latanoprost.
PhentolamineLatanoprost may increase the hypotensive activities of Phentolamine.
PinacidilLatanoprost may increase the hypotensive activities of Pinacidil.
PindololLatanoprost may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Latanoprost.
PivhydrazinePivhydrazine may increase the hypotensive activities of Latanoprost.
PolythiazideLatanoprost may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Latanoprost.
PropranololPropranolol may increase the hypotensive activities of Latanoprost.
QuinaprilLatanoprost may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Latanoprost.
RamiprilRamipril may increase the hypotensive activities of Latanoprost.
RasagilineRasagiline may increase the hypotensive activities of Latanoprost.
RemikirenRemikiren may increase the hypotensive activities of Latanoprost.
RescinnamineLatanoprost may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Latanoprost.
RiociguatLatanoprost may increase the hypotensive activities of Riociguat.
RituximabLatanoprost may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Latanoprost.
SaprisartanLatanoprost may increase the hypotensive activities of Saprisartan.
SelegilineSelegiline may increase the hypotensive activities of Latanoprost.
SelexipagLatanoprost may increase the hypotensive activities of Selexipag.
SildenafilSildenafil may increase the antihypertensive activities of Latanoprost.
SitaxentanLatanoprost may increase the hypotensive activities of Sitaxentan.
SpiraprilLatanoprost may increase the hypotensive activities of Spirapril.
TadalafilTadalafil may increase the antihypertensive activities of Latanoprost.
TelmisartanLatanoprost may increase the hypotensive activities of Telmisartan.
TemocaprilLatanoprost may increase the hypotensive activities of Temocapril.
TerlipressinLatanoprost may increase the hypotensive activities of Terlipressin.
TiboloneLatanoprost may increase the hypotensive activities of Tibolone.
TicrynafenLatanoprost may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Latanoprost.
TolazolineLatanoprost may increase the hypotensive activities of Tolazoline.
ToloxatoneToloxatone may increase the hypotensive activities of Latanoprost.
TorasemideTorasemide may increase the hypotensive activities of Latanoprost.
TrandolaprilTrandolapril may increase the hypotensive activities of Latanoprost.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Latanoprost.
TranylcypromineTranylcypromine may increase the hypotensive activities of Latanoprost.
TravoprostTravoprost may increase the hypotensive activities of Latanoprost.
TreprostinilTreprostinil may increase the hypotensive activities of Latanoprost.
TrichlormethiazideLatanoprost may increase the hypotensive activities of Trichlormethiazide.
TrimazosinLatanoprost may increase the hypotensive activities of Trimazosin.
TrimethaphanLatanoprost may increase the hypotensive activities of Trimethaphan.
UdenafilUdenafil may increase the antihypertensive activities of Latanoprost.
UnoprostoneLatanoprost may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Latanoprost.
VardenafilVardenafil may increase the antihypertensive activities of Latanoprost.
XylometazolineLatanoprost may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Latanoprost.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin f receptor activity
Specific Function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and ...
Gene Name:
PTGFR
Uniprot ID:
P43088
Molecular Weight:
40054.1 Da
References
  1. Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63. [PubMed:16249494 ]
  2. Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, Hara H: New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003 Dec;26(12):1691-5. [PubMed:14646172 ]
  3. Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H: Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004 Apr;78(4):767-76. [PubMed:15037111 ]
  4. Ocklind A: Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998 Aug;67(2):179-91. [PubMed:9733584 ]
  5. Maxey KM, Johnson JL, LaBrecque J: The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S34-40. [PubMed:12204699 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Kraft ME, Glaeser H, Mandery K, Konig J, Auge D, Fromm MF, Schlotzer-Schrehardt U, Welge-Lussen U, Kruse FE, Zolk O: The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. doi: 10.1167/iovs.09-4290. Epub 2009 Dec 17. [PubMed:20019365 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. [PubMed:11907186 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23